Insider Trading Alert - PRXL, BLK And BYI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 12, 2014, 128 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $79.73 to $121,490,730.00.

Highlighted Stocks Traded by Insiders:

Parexel International Corporation (PRXL) - FREE Research Report

Von Rickenbach Josef H who is Chairman & CEO at Parexel International Corporation sold 50,000 shares at $49.76 on Feb. 12, 2014. Following this transaction, the Chairman & CEO owned 562,641 shares meaning that the stake was reduced by 8.16% with the 50,000-share transaction.

Callow A Dana Jr who is Director at Parexel International Corporation sold 10,000 shares at $49.40 on Feb. 12, 2014. Following this transaction, the Director owned 33,990 shares meaning that the stake was reduced by 22.73% with the 10,000-share transaction.

The shares most recently traded at $51.66, up $2.26, or 4.37% since the insider transaction. Historical insider transactions for Parexel International Corporation go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 79,529
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 79,529
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 86,529

The average volume for Parexel International Corporation has been 672,500 shares per day over the past 30 days. Parexel International Corporation has a market cap of $2.8 billion and is part of the health care sector and health services industry. Shares are up 12.17% year-to-date as of the close of trading on Wednesday.

PAREXEL International Corporation, a biopharmaceutical services company, provides clinical research, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology, and medical device industries worldwide. The company has a P/E ratio of 25.5. Currently there are 5 analysts that rate Parexel International Corporation a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PRXL - FREE

TheStreet Quant Ratings rates Parexel International Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Parexel International Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

With Hurricane Harvey, We Are in the Crosshairs of Volatility: Market Recon

EY's Greene Sees More Med Tech, CRO Deals Ahead

Stocks Lower as Crude Oil Slides on Supply Concerns

Stock Futures Narrowly Mixed as Oil Plunges to Fresh 2017 Low